News - elvitegravir

Filter

Current filters:

elvitegravir

Popular Filters

US FDA delays approval of Gilead's elvitegravir and cobicistat for HIV

30-04-2013

US antiviral drug specialists Gilead Sciences (Nasdaq: GILD) says it has received Complete Response Letters…

Anti-viralsBiotechnologycobicistatelvitegravirGilead SciencesNorth AmericaRegulation

Japan Tobacco files for Japanese approval of elvitegravir

11-12-2012

Japan Tobacco (TSE:2914) has filed a New Drug Application for marketing approval of a novel anti-HIV…

Anti-viralsAsia-PacificBiotechnologyelvitegravirGilead SciencesJapan TobaccoPharmaceuticalRegulationTorii Pharma

Batch of clinical trial results for Gilead's elvitegravir, Complera and cobicistat

25-07-2012

US biotech firm Gilead Sciences (Nasdaq: GILD), the world's biggest producer of HIV treatments, announced…

Anti-viralsBiotechnologycobicistatCompleraelvitegravirGilead SciencesResearch

Gilead files elvitegravir and cobicistat with FDA; AHF plea on Quad pricing

29-06-2012

US biotech firm Gilead Sciences (Nasdaq: GILD), world's largest maker of HIV drugs, has submitted a New…

Anti-viralsBiotechnologycobicistatelvitegravirGilead SciencesNorth AmericaPricingQuadRegulation

Back to top